Topics

Insurance companies selling health plans next fall for coverage in 2015 are asking state regulators to approve prices that reflect medical-cost inflation, and, in some cases, federal mandates, and expensive drugs to treat Hepatitis C. Anthem Blue Cross and Blue Shield in Connecticut and ConnectiCare are asking for increases. HealthyCT is asking for a price decrease. Summaries of the proposed rate increases were posted this week on the Connecticut Insurance Department's website. Insurers were required to file 2015 rates by May 31 for review by the department, which could approve, modify or deny them. The insurance plans will be available next fall to customers who buy insurance...

U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers.
In a letter to the Foster City, Calif., company, Rep. Henry A....

The federal government has approved for the first time a drug that can prevent an HIV infection, a significant development for Baltimore where transmission rates for the virus remain high and growing.
The U.S. Food and Drug Administration approved...

LOS ANGELES/GENEVA (Reuters) - Fewer people infected with HIV globally are dying as more of them get access to crucial antiretroviral drugs, particularly in sub-Saharan Africa, the United Nations AIDS program said on Wednesday. The United Nations...

NEW YORK (Reuters) - The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it and suggested that poor and wealthy countries alike set up pilot projects to better...

(Reuters) - U.S. health regulators on Monday approved Gilead Sciences Inc's four-drug combination pill to treat HIV, the virus that causes AIDS. The four drugs in one pill, which was formerly called the Quad and had been considered one of Gilead's more...

Groups working on a gel to protect women from the AIDS virus say they are moving ahead to develop the product that was hailed as "groundbreaking" after a study on its effectiveness was released in July.
The developers, who met last week with...